• Reserpine (N1867): Technical Guidance for Neuropharmacology

  2026-04-25

  Reserpine (SKU N1867) enables rigorous neurotransmitter depletion and antihypertensive mechanism studies by providing a high-purity, workflow-validated compound. Researchers should use this product within well-defined experimental parameters and avoid long-term solution storage to ensure consistency. Not suitable for diagnostic or medical applications.

• Estradiol-ERα Signaling Restores CD4+ T Cells After Hemorrha

  2026-04-24

  This study demonstrates that 17β-estradiol (E2) normalizes splenic CD4+ T lymphocyte function after hemorrhagic shock by suppressing endoplasmic reticulum stress via ERα and GPR30, but not ERβ. The findings highlight specific estrogen receptor pathways in immunomodulation following trauma, providing mechanistic clarity for future endocrine and immune research.

• Curcumin Suppresses NLRP3-Mediated Pyroptosis in Endothelial

  2026-04-24

  This study demonstrates that curcumin inhibits hydrogen peroxide-induced pyroptosis in human umbilical vein endothelial cells (HUVECs) by targeting the NLRP3 inflammasome. The findings clarify the mechanistic basis for curcumin’s protective effects in endothelial dysfunction, highlighting translational opportunities for inflammatory disease research.

• Canagliflozin Remodels Mitochondria in Diabetic Mouse Kidney

  2026-04-23

  This study reveals that canagliflozin, a selective SGLT2 inhibitor, not only lowers glucose but also remodels mitochondrial structure and improves bioenergetic function in proximal tubular cells of hypertensive–diabetic mice. These findings provide mechanistic insight into renal protective effects, expanding the therapeutic relevance of SGLT2 inhibitors in kidney disease research.

• L-Alanyl-L-Glutamine: Enhancing Intestinal Barrier Research

  2026-04-23

  L-Alanyl-L-glutamine stands apart as a stable, absorption-enhancing dipeptide that optimizes intestinal barrier workflows and experimental reproducibility. This article details applied protocols, troubleshooting strategies, and comparative advantages, anchoring the molecule's role as a research catalyst for mucosal protection and inflammation attenuation.

• GLI2 Drives Tumor Immune Evasion via WNT and Prostaglandin S

  2026-04-22

  This study establishes GLI2 as a central regulator of tumor-mediated immune evasion and resistance to immunotherapy by coordinating WNT ligand secretion and prostaglandin synthesis. These mechanisms promote recruitment of immunosuppressive myeloid cells and impair anti-tumor immunity, revealing actionable targets for combination cancer therapies.

• Lanabecestat (AZD3293): Protocols & Precision in Alzheimer’s

  2026-04-22

  Lanabecestat (AZD3293) stands out as a potent, blood-brain barrier-penetrant BACE1 inhibitor, empowering Alzheimer’s disease researchers with synaptic-sparing modulation of amyloid-beta production. This article unpacks applied workflows, assay optimization strategies, and troubleshooting tips, translating the latest reference findings into actionable guidance for robust, reproducible experiments.

• Applied Workflows with Foretinib (GSK1363089) in Cancer Rese

  2026-04-21

  Foretinib (GSK1363089) sets a new benchmark for multikinase inhibition, enabling precise tumor cell growth and metastasis studies across diverse models. This guide delivers actionable protocols, troubleshooting insights, and evidence-driven workflow enhancements for maximizing Foretinib’s translational impact.

• ARCA Cy5 EGFP mRNA (5-moUTP): Precision in mRNA Delivery Ana

  2026-04-21

  ARCA Cy5 EGFP mRNA (5-moUTP) stands out as a dual-labeled, 5-methoxyuridine modified mRNA reporter, enabling direct visualization and quantification of mRNA delivery, localization, and translation efficiency in mammalian cells. This tool empowers reproducible, immune-evasive, and multiplexed workflows, advancing both routine and cutting-edge mRNA research.

• SP2509: Lysine-specific Demethylase 1 Antagonist for AML Res

  2026-04-20

  SP2509 empowers cancer epigenetics researchers with a highly selective LSD1 inhibition platform, enabling robust apoptosis induction and differentiation in AML models. This article details experimental workflows, troubleshooting guidance, and strategic positioning, showcasing SP2509's unique role in translational AML research.

• DiscoveryProbe Bioactive Compound Library Plus in High-Throu

  2026-04-20

  Accelerate ligand discovery and mechanistic pathway analysis with the DiscoveryProbe™ Bioactive Compound Library Plus—a rigorously validated, cell-permeable small molecule set that streamlines high-throughput screening and advanced target validation. See how evidence-based workflows, troubleshooting strategies, and comparative insights can transform your apoptosis and signaling research.

• ALT Cancer Cells: ATR Inhibitor Sensitivity Revisited

  2026-04-19

  This study rigorously re-examines the hypothesis that cancer cells using alternative lengthening of telomeres (ALT) are broadly hypersensitive to ATR inhibition. Contrary to prior reports, Deeg et al. show ALT status alone does not confer general hypersensitivity, challenging the basis for ALT-selective ATR inhibitor therapies and highlighting the need for careful viability assay design.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-04-18

  DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe enables high-contrast, lipophilic plasma membrane labeling in live and fixed cells, particularly benefitting neuronal tracing and cell migration assay workflows. It is unsuitable for water-based protocols or organelle-specific labeling, making careful protocol design and storage essential for reproducible results.

• Eltanexor (KPT-8602): Enhancing Cancer Models via XPO1 Inhib

  2026-04-17

  Eltanexor (KPT-8602) from APExBIO empowers oncology researchers with a potent, well-tolerated XPO1 inhibitor, uniquely suited for dissecting nuclear export in hematologic and solid tumor models. This guide details actionable workflows, application-specific protocols, and troubleshooting tips to maximize data quality and translational relevance in cancer therapeutics research.

• Repurposing Vitamins as SARS-CoV-2 Protease Inhibitors: Dock

  2026-04-16

  This study systematically screens natural vitamin compounds for their ability to inhibit SARS-CoV-2's main protease (3CLpro) and the receptor-binding domain (RBD) of the spike protein using in silico methods. The findings highlight several safe, accessible vitamins with stable binding to critical viral targets, offering new directions for antiviral therapeutics research.

16293 records 1/1087 page Next 12345 下5页 Last page